NYU Grossman School of Medicine, New York, New York, USA.
Department of Otolaryngology-Head and Neck Surgery, NYU Langone, New York, New York, USA.
Laryngoscope. 2023 Oct;133(10):2654-2664. doi: 10.1002/lary.30571. Epub 2023 Jan 30.
To compare outcomes between two standard-of-care anesthesia regimens for operative laryngoscopy: general anesthesia with a neuromuscular blocking agent (NMBA) versus remifentanil and propofol (non-NMBA).
This was a prospective, single-blinded, randomized controlled trial at a tertiary care center. Patients were randomized to either anesthesia using rocuronium (NMBA) or with remifentanil/propofol infusion alone (non-NMBA). Intraoperative impressions, anesthesia data, and post-operative patient surveys were collected.
Sixty-one patients who underwent suspension laryngoscopy from 2020 to 2022 were included (25 female, 36 male, ranging 20-81 years). Thirty patients were enrolled in the NMBA arm and 31 patients in the non-NMBA arm. Heart rate and mean arterial pressure were higher in the NMBA (p < 0.01). Patients in the non-NMBA group were more likely to require vasopressors (p = 0.04, RR = 3.08 [0.86-11.05]). Surgeons were more frequently satisfied with conditions in the NMBA group (86.7%) compared to the non-NMBA group (58.1%, p < 0.01). Procedures were more likely to be paused due to movement in the non-NMBA group (45.1%) compared to the NMBA group (16.6%, p < 0.03, RR = 2.26 [1.02-4.99]). Patients in the non-NMBA group were more likely to endorse myalgia the week after surgery (44%) compared to the NMBA group (8.3%, p < 0.01) and reported higher average pain levels on a 0-10 pain scale (3.7) compared to the paralysis group (2.0).
Anesthesia with rocuronium was associated with better intraoperative conditions and postoperative pain compared to anesthesia with remifentanil/propofol. Remifentanil/propofol were associated with lower blood pressure and suppression of laryngoscopy-associated tachycardia.
2 Laryngoscope, 133:2654-2664, 2023.
比较两种标准的手术喉镜麻醉方案的结果:使用神经肌肉阻滞剂的全身麻醉(NMBA)与瑞芬太尼和丙泊酚(非 NMBA)。
这是在一家三级保健中心进行的前瞻性、单盲、随机对照试验。患者随机分为使用罗库溴铵(NMBA)麻醉或单独使用瑞芬太尼/丙泊酚输注麻醉(非 NMBA)。收集术中印象、麻醉数据和术后患者调查。
2020 年至 2022 年期间,共有 61 名接受悬雍垂切除术的患者入组(25 名女性,36 名男性,年龄 20-81 岁)。30 名患者纳入 NMBA 组,31 名患者纳入非 NMBA 组。NMBA 组的心率和平均动脉压较高(p<0.01)。非 NMBA 组的患者更有可能需要血管加压药(p=0.04,RR=3.08[0.86-11.05])。外科医生更频繁地对 NMBA 组的条件感到满意(86.7%),而对非 NMBA 组的条件满意(58.1%,p<0.01)。由于非 NMBA 组的运动,手术更有可能暂停(45.1%),而 NMBA 组暂停(16.6%,p<0.03,RR=2.26[1.02-4.99])。非 NMBA 组的患者在手术后一周更有可能出现肌肉痛(44%),而 NMBA 组的患者则为 8.3%(p<0.01),并且在 0-10 疼痛量表上报告的平均疼痛水平更高(3.7),而非 NMBA 组的患者则为 2.0。
与瑞芬太尼/丙泊酚麻醉相比,罗库溴铵麻醉与更好的术中条件和术后疼痛相关。瑞芬太尼/丙泊酚与较低的血压和抑制喉镜相关的心动过速有关。
2 级喉镜,133:2654-2664,2023 年。